A multiinstitutional, concurrent chemoradiation trial of strontium‐89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone

Akerley, Wallace; Butera, James N.; Wehbe, Terek; Noto, Richard B.; Stein, Barry S.; Safran, Howard; Cummings, Frank J.; Sambandam, Sundaresan; Maynard, John F.; Rienzo, Gregory Di; Leone, Louis A.

doi:10.1002/cncr.10437

Cited by 57 publications

(17 citation statements)

References 38 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies regarding Sr-89 involved patients who had received chemotherapy before Sr-89 administration, presenting it as a background factor. Akerley et al (13), Tu et al (14) and Sciuto et al (15) reported simultaneous combination therapy with Sr-89 and chemotherapeutic agents in patients with prostate cancer and observed tolerance. Furthermore, Tu et al (16) and Porfini et al (17) investigated whether or not chemotherapy can be performed after Sr-89 administration in prostate cancer patients, and concluded that chemotherapy was possible.…”

Section: Discussionmentioning

confidence: 99%

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Yamada

Yoshimura

Kojima

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Our aim in this study was to examine the safety and efficacy of the concurrent use of the radiopharmaceutical strontium-89 (Sr-89) chloride with zoledronic acid in standard anticancer therapy for breast cancer patients with painful multifocal bone metastases. The study comprised 16 breast cancer patients with painful multifocal bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging. All patients were treated with Sr-89 and zoledronic acid concurrently between March 2007 and February 2011 as part of a standard therapeutic regimen comprising chemotherapy, endocrine therapy, molecular targeting therapy and targeted radiotherapy. Sr-89 was administered intravenously at 2 MBq/kg to a maximum of 141 MBq per person. Safety was evaluated according to myelotoxicity as measured by the Common Terminology Criteria for Adverse Events (v3.0). To assess treatment efficacy, we monitored changes in analgesic drug dosages. Furthermore, bremsstrahlung imaging after the administration of Sr-89 was utilized to examine the relationship between the accumulation of Sr-89 in metastatic sites and treatment efficacy. Based on the results, a total of 14 out of 16 patients (88%) reported bone pain relief, indicating a high efficacy of Sr-89 combined with zoledronic acid. In responsive cases, a strong uptake of Sr-89 was observed on bremsstrahlung imaging at the same sites indicated by 99m Tc bone scintigraphy. Moreover, severe myelosuppression (> grade 3) was not observed, and adverse events were tolerable. In conclusion, the use of Sr-89 with zoledronic acid in breast cancer patients with painful bone metastases was safe and effective when administered concurrently with other standard therapies. In the future, the treatment with Sr-89 at the early stage should be considered, and a large-scale clinical study should be conducted.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Yamada

Yoshimura

Kojima

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…52,53 NCI-3410 is a Phase III trial to compare the effectiveness of chemotherapy with or without strontium-89 in treating patients who have prostate cancer that has spread to the bone. 54 Patients receive one of two chemotherapy regimens for 6 weeks.…”

Section: Local and Systemic Radiation For Palliationmentioning

confidence: 99%

Advances in Prostate Cancer Chemotherapy: A New Era Begins

Pienta

Smith

2005

CA: A Cancer Journal for Clinicians

161

124

View full text Add to dashboard Cite

Prostate cancer continues to be the most common lethal malignancy diagnosed in American men and the second leading cause of male cancer mortality. Over 60 years ago, Huggins and Hodges discovered androgen deprivation as a first-line therapy for metastatic prostate cancer, which leads to remissions typically lasting 2 to 3 years, but in most men prostate cancer ultimately progresses to an androgen-independent state resulting in death due to widespread metastases. Multiple mechanisms of androgen independence have now been documented, including amplification of the androgen receptor as well as signal transduction pathways that bypass the androgen receptor completely. In 2004, two landmark studies demonstrated a survival advantage in androgen-independent prostate cancer patients utilizing docetaxel chemotherapy, setting a new standard of care for this disease. In addition, treatments with the bisphosphonate zoledronic acid and systemic radioisotopes have also been shown to have palliative benefits in this population. Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development. (CA Cancer J Clin 2005;55:300-318.)

show abstract

“…These radionuclides are betaemitting radioisotopes that differ primarily in their radioactive half-lives and the tissue penetrance of their beta particles. Adding systemic radioisotopes to chemotherapy regimens for patients with advanced prostate cancer appears to increase response rates and survival [Tu et al, 2001;Akerley et al, 2002]. Further exploration of how this could be applied to the human disease setting is being investigated in preclinical and clinical settings.…”

Section: Targeting the Stromal Cellsmentioning

confidence: 99%

A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions

Loberg

Gayed

Olson

et al. 2005

J of Cellular Biochemistry

View full text Add to dashboard Cite

The pliability of cancer cells to mutate into several different phenotypes in an attempt to find one that will survive and colonize at the metastatic site is a tremendous ''hurdle'' to overcome in designing novel cancer therapeutics. New targets of therapy are essential if we are to effectively overcome the evasiveness of cancer. The interaction between the tumor cell and the surrounding microenvironment creates a vicious cycle that perpetuates disease survival and progression. The future of cancer therapy resides in the ability to focus on the recruited and exploited relationships of the cancer cell with the host environment. These therapies target cancer cell growth early and interrupt the vicious cycle that is created by the tumor cells interacting with bone components by inhibiting osteoclasts, osteoblasts, stromal cells, and endothelial cells. They alter the bone microenvironment, creating a hostile ''soil'' that prevents the ''seed'' from developing into bone metastases and represent a potential new platform for the development of prostate cancer therapeutics.

show abstract

A multiinstitutional, concurrent chemoradiation trial of strontium‐89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone

Cited by 57 publications

References 38 publications

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases

Advances in Prostate Cancer Chemotherapy: A New Era Begins

A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions

Contact Info

Product

Resources

About